OptimizeRx (OPRX) said Monday that Chief Executive William J. Febbo will leave the company, effective Dec. 31 and that it appointed Stephen Silvestro as interim CEO.
The digital health technology company said its board hired a search firm to assist in the transition and to help look for a successor. Silvestro was the company's chief commercial officer before becoming president last year, OptimizeRx said.
OptimizeRx said it expects full-year 2024 revenue to come in at the higher end of the $88 million to $92 million guidance range.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。